Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. Its main revenue sources include small molecules (approximately 40%), biologics (approximately 50%), and CAR-T cell therapies (approximately 10%). The company's customers primarily include healthcare providers, hospitals, and patients. Factors supporting its endurance include a strong pipeline of drugs and a history of successful product launches, while patent expirations and regulatory challenges could limit its revenue growth.
—
Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. Its main revenue sources include small molecules (approximately 40%), biologics (approximately 50%), and CAR-T cell therapies (approximately 10%). The company's customers primarily include healthcare providers, hospitals, and patients. Factors supporting its endurance include a strong pipeline of drugs and a history of successful product launches, while patent expirations and regulatory challenges could limit its revenue growth.
—
Daily adjusted close
Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. Its main revenue sources include small molecules (approximately 40%), biologics (approximately 50%), and CAR-T cell therapies (approximately 10%). The company's customers primarily include healthcare providers, hospitals, and patients. Factors supporting its endurance include a strong pipeline of drugs and a history of successful product launches, while patent expirations and regulatory challenges could limit its revenue growth.